药品注册申请号:020232
申请类型:NDA (新药申请)
申请人:ACTAVIS LABS UT INC
申请人全名:ACTAVIS LABORATORIES UT INC
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 FIORICET W/ CODEINE ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE CAPSULE;ORAL 325MG;50MG;40MG;30MG Yes Yes AB 1992/07/30 1992/07/30 Prescription
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2023/12/15 SUPPL-47(补充) Approval Labeling STANDARD
2021/03/04 SUPPL-45(补充) Approval Labeling STANDARD
2019/10/07 SUPPL-44(补充) Approval Labeling STANDARD
2018/09/18 SUPPL-43(补充) Approval Labeling STANDARD
2018/09/18 SUPPL-42(补充) Approval REMS N/A
2017/08/29 SUPPL-41(补充) Approval Labeling STANDARD
2016/12/16 SUPPL-40(补充) Approval Labeling STANDARD
2015/07/31 SUPPL-39(补充) Approval Manufacturing (CMC) STANDARD
2015/06/16 SUPPL-38(补充) Approval Manufacturing (CMC) STANDARD
2014/06/05 SUPPL-37(补充) Approval Manufacturing (CMC) STANDARD
2013/10/18 SUPPL-36(补充) Approval Labeling STANDARD
2013/05/09 SUPPL-35(补充) Approval Labeling 901 REQUIRED
2011/06/22 SUPPL-33(补充) Approval Labeling UNKNOWN
2008/03/21 SUPPL-21(补充) Approval Labeling STANDARD
2002/04/26 SUPPL-16(补充) Approval Manufacturing (CMC) STANDARD
2002/01/03 SUPPL-15(补充) Approval Manufacturing (CMC) STANDARD
2001/10/04 SUPPL-12(补充) Approval Labeling STANDARD
2001/05/30 SUPPL-13(补充) Approval Manufacturing (CMC) STANDARD
2001/05/22 SUPPL-14(补充) Approval Manufacturing (CMC) STANDARD
1999/08/03 SUPPL-10(补充) Approval Manufacturing (CMC) STANDARD
1999/04/22 SUPPL-9(补充) Approval Manufacturing (CMC) STANDARD
1998/05/20 SUPPL-8(补充) Approval Labeling STANDARD
1996/01/18 SUPPL-4(补充) Approval Labeling STANDARD
1995/11/08 SUPPL-5(补充) Approval Manufacturing (CMC) STANDARD
1994/03/29 SUPPL-2(补充) Approval Manufacturing (CMC) STANDARD
1992/12/01 SUPPL-1(补充) Approval Manufacturing (CMC) STANDARD
1992/07/30 ORIG-1(原始申请) Approval Type 5 - New Formulation or New Manufacturer STANDARD
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
与本品治疗等效的药品
活性成分:ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE 剂型/给药途径:CAPSULE;ORAL 规格:325MG;50MG;40MG;30MG 治疗等效代码:AB
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
020232 001 NDA FIORICET W/ CODEINE ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE CAPSULE;ORAL 325MG;50MG;40MG;30MG Prescription Yes Yes AB 1992/07/30 ACTAVIS LABS UT INC
075929 001 ANDA BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE CAPSULE;ORAL 325MG;50MG;40MG;30MG Prescription No No AB 2002/04/22 NOSTRUM LABS INC
076560 001 ANDA BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE CAPSULE;ORAL 325MG;50MG;40MG;30MG Prescription No No AB 2004/06/10 LGM PHARMA
204649 001 ANDA BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE CAPSULE;ORAL 325MG;50MG;40MG;30MG Prescription No No AB 2020/07/08 STRIDES PHARMA
215138 001 ANDA BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE CAPSULE;ORAL 325MG;50MG;40MG;30MG Prescription No No AB 2022/01/26 HIKMA
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2024 DrugFuture->U.S. FDA Drugs Database